Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

about

Chemical Stability of Plerixafor after Opening of Single-Use Vial.

P2860

Q47104652-C44032C2-4522-4F2A-9084-C05FB9F44970

P2860

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

Item

http://www.wikidata.org/entity/Q42380588

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Plerixafor for autologous stem ...... ation for patients in Ontario.

@en

Plerixafor for autologous stem ...... ation for patients in Ontario.

@nl

type

Item

label

Plerixafor for autologous stem ...... ation for patients in Ontario.

@en

Plerixafor for autologous stem ...... ation for patients in Ontario.

@nl

prefLabel

Plerixafor for autologous stem ...... ation for patients in Ontario.

@en

Plerixafor for autologous stem ...... ation for patients in Ontario.

@nl

P1476

Plerixafor for autologous stem ...... ation for patients in Ontario.

@en

P2093

A Xenocostas

http://www.w3.org/2001/XMLSchema#string

C Bredeson

http://www.w3.org/2001/XMLSchema#string

C T Kouroukis

http://www.w3.org/2001/XMLSchema#string

J Kuruvilla

http://www.w3.org/2001/XMLSchema#string

N P Varela

http://www.w3.org/2001/XMLSchema#string

P2860

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.

AGREE II: advancing guideline development, reporting and evaluation in health care.

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience

Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

P304

e409-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.23.3137

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27536190

http://www.w3.org/2001/XMLSchema#string

P932

4974047

http://www.w3.org/2001/XMLSchema#string

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

about

P2860

P2860

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932